Metsera (MTSR) – Research Analysts’ Recent Ratings Changes

Metsera (NASDAQ: MTSR) has recently received a number of price target changes and ratings updates:

• 10/8/2025 – Metsera had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 10/1/2025 – Metsera was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 9/30/2025 – Metsera was downgraded by analysts at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating. They now have a $54.00 price target on the stock.
• 9/27/2025 – Metsera had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 9/24/2025 – Metsera had its “market perform” rating reaffirmed by analysts at Leerink Partners. They now have a $57.00 price target on the stock, down previously from $77.00.
• 9/24/2025 – Metsera was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
• 9/23/2025 – Metsera was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 9/15/2025 – Metsera was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 9/9/2025 – Metsera was upgraded by analysts at Leerink Partnrs to a “strong-buy” rating.
• 9/9/2025 – Metsera is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $77.00 price target on the stock.
• 9/7/2025 – Metsera was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 9/3/2025 – Metsera had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 8/30/2025 – Metsera was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 8/28/2025 – Metsera had its price target raised by analysts at Bank of America Corporation from $45.00 to $50.00. They now have a “buy” rating on the stock.

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.